Shp2 suppresses PyMT-induced transformation in mouse fibroblasts by inhibiting Stat3 activity

Virology

Volumn 409, Issue 2, 2011, Pages 204-210

  Yang, Ying ^a   Jiang, Beibei ^a   Huo, Yingqing ^a   Primo, Luca ^b   Dahl, Jean S ^c   Benjamin, Thomas L ^c   Luo, Jincai ^a  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF TURIN   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Fibroblasts; Oncogene; Polyoma middle T antigen; Shp2; Signal transduction; Transformation

Indexed keywords

ONCOPROTEIN; PROTEIN KINASE P60; PROTEIN TYROSINE PHOSPHATASE SHP 2; SHORT HAIRPIN RNA; STAT3 PROTEIN; VIRUS MIDDLE T ANTIGEN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENE MUTATION; GENE OVEREXPRESSION; INHIBITION KINETICS; LEUKEMOGENESIS; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; MICE; MICE, INBRED BALB C; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; STAT3 TRANSCRIPTION FACTOR;

POLYOMAVIRUS;

EID: 78650293525     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.09.032     Document Type: Article

References (39)

1. Brewster C.E., Glover H.R., Dilworth S.M. pp 60c-src binding to polyomavirus middle T-antigen (MT) requires residues 185 to 210 of the MT sequence. J. Virol. 1997, 71:5512-5520.
2. Bronson R., Dawe C., Carroll J., Benjamin T. Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc. Proc. Natl Acad. Sci. USA 1997, 94:7954-7958.
3. Campbell K.S., Auger K.R., Hemmings B.A., Roberts T.M., Pallas D.C. Identification of regions in polyomavirus middle T and small t antigens important for association with protein phosphatase 2A. J. Virol. 1995, 69:3721-3728.
4. Chan R.J., Feng G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007, 109:862-867.
5. Cheng J., DeCaprio J.A., Fluck M.M., Schaffhausen B.S. Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens. Semin. Cancer Biol. 2009, 19:218-228. Review.
6. Dahl J., Freund R., Blenis J., Benjamin T.L. Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3-kinase in activation of pp 70 S6 kinase. Mol. Cell. Biol. 1996, 16:2728-2735.
7. Dahl J., Jurczak A., Cheng L.A., Baker D.C., Benjamin T.L. Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen. J. Virol. 1998, 72:3221-3226.
8. Dance M., Montagner A., Salles J.P., Yart A., Raynal P. The molecular functions of Shp2 in the Ras/mitogen-activated protein kinase (ERK1/2) pathway. Cell. Signal. 2008, 20:453-459.
9. Dilworth S.M., Brewster C.E.P., Jones M.D., Lanfrancone L., Pelicci G., Pelicci P.G. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature 1994, 367:87-90.
10. Dilworth S.M. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat. Rev. Cancer 2002, 2:951-956.
11. Druker B.J., Sibert L., Roberts T.M. Polyomavirus middle T-antigen NPTY mutants. J. Virol. 1992, 66:5770-5776.
12. Durocher Y., Perret S., Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002, 30:E9.
13. Edouard T., Montagner A., Dance M., Conte F., Yart A., Parfait B., Tauber M., Salles J.P., Raynal P. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?. Cell. Mol. Life Sci. 2007, 64:1585-1590.
14. Feng G.S. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp. Cell Res. 1999, 253:47-54.
15. Feng G.S. Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation. Cell Res. 2007, 17:37-41.
16. Fluck M.M., Schaffhausen B.S. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 2009, 73:542-563.
17. Garcia R., Yu C.L., Hudnall A., Catlett R., Nelson K.L., Smithgall T., Fujita D.J., Ethier S.P., Jove R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997, 8:1267-1276.
18. Gauthier A.S., Furstoss O., Araki T., Chan R., Neel B.G., Kaplan D.R., Miller F.D. Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron 2007, 54:245-262.
19. Ichaso N., Dilworth S.M. Cell transformation by the middle T-antigen of polyoma virus. Oncogene 2001, 20:7908-7916.
20. Ischenko I., Petrenko O., Gu H., Hayman M.J. Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase. Oncogene 2003, 22:6311-6318.
21. Jazayeri A., McGee J., Shimamura T., Cross S.B., Bejcek B.E. SHP-2 can suppress transformation induced by platelet-derived growth factor. Exp. Cell Res. 2000, 254:197-203.
22. Kalakonda S., Nallar S.C., Lindner D.J., Hu J., Reddy S.P., Kalvakolanu D.V. Tumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res. 2007, 67:6212-6220.
23. Kontaridis M.I., Swanson K.D., David F.S., Barford D., Neel B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 2006, 281:6785-6792.
24. Luo J.C., Yamaguchi S., Shinkai A., Shitara K., Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998, 58:2652-2660.
25. Mohi M.G., Neel B.G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 2007, 17:23-30.
26. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28:284-293.
27. Oh E.S., Gu H., Saxton T.M., Timms J.F., Hausdorff S., Frevert E.U., Kahn B.B., Pawson T., Neel B.G., Thomas S.M. Regulation of early events in integrin signaling by protein tyrosine phosphatase SHP-2. Mol. Cell. Biol. 1999, 19:3205-3215.
28. Ong S.H., Dilworth S., Hauck-Schmalenberger I., Pawson T., Kiefer F. ShcA and Grb2 mediate polyoma middle T antigen-induced endothelial transformation and Gab1 tyrosine phosphorylation. EMBO J. 2001, 20:6327-6336.
29. Ogris E., Mudrak I., Mak E., Gibson D., Pallas D.C. Catalytically inactive protein phosphatase 2A can bind to polyomavirus middle tumor antigen and support complex formation with pp 60c-src. J. Virol. 1999, 73:7390-7398.
30. Pallas D.C., Schley C., Mahoney M., Harlow E., Schaffhausen B.S., Roberts T.M. Polyomavirus small t antigen: overproduction in bacteria, purification, and utilization for monoclonal and polyclonal antibody production. J. Virol. 1986, 60:1075-1084.
31. Raptis L., Lamfrom H., Benjamin T.L. Regulation of cellular phenotype and expression of polyomavirus middle T antigen in rat fibroblasts. Mol. Cell. Biol. 1985, 5:2476-2486.
32. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 2005, 331:1-14. Review.
33. Schaffhausen B.S., Roberts T.M. Lessons from polyoma middle T antigen on signaling and transformation: a DNA tumor virus contribution to the war on cancer. Virology 2009, 384:304-316.
34. Sedy J.R., Gavrieli M., Potter K.G., Hurchla M.A., Lindsley R.C., Hildner K., Scheu S., Pfeffer K., Ware C.F., Murphy T.L., Murphy K.M. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 2005, 6:90-98.
35. Talmage D.A., Freund R., Young A.T., Dahl J., Dawe C.J., Benjamin T.L. Phosphorylation of middle T by pp 60c-src: a switch for binding of phosphatidylinositol 3-kinase and optimal tumorigenesis. Cell 1989, 59:55-65.
36. Xiong Y., Huo Y., Chen C., Zeng H., Lu X., Wei C., Ruan C., Zhang X., Hu Z., Shibuya M., Luo J. Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways. J. Biol. Chem. 2009, 284:23217-23224.
37. Yu M., Luo J., Yang W., Wang Y., Mizuki M., Kanakura Y., Besmer P., Neel B.G., Gu H. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J. Biol. Chem. 2006, 281:28615-28626.
38. Zhang S.Q., Tsiaras W.G., Araki T., Wen G., Minichiello L., Klein R., Neel B.G. Receptor-specific regulation of phosphatidylinositol 3?-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell. Biol. 2002, 22:4062-4072.
39. Zhang S.Q., Yang W., Kontaridis M.I., Bivona T.G., Wen G., Araki T., Luo J., Thompson J.A., Schraven B.L., Philips M.R., Neel B.G. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 2004, 13:341-355.